BERLIN, January 7, 2025 — Pentixapharm AG, a radiopharmaceutical innovator, has received €6.77 million from unnamed Asian pharmaceutical and biotech firms for intangible assets previously developed by Glycotope. This transaction, finalized in 2024, covers rights transferred to Pentixapharm as part of its July 2024 acquisition of Glycotope’s target discovery operations.
“This deal virtually eliminates our remaining earn-out obligations from the target discovery business acquisition,” stated Henner Kollenberg, Chief Business Officer. “While it won’t significantly impact Pentixapharm’s 2024 losses, it enables the monetization of other Glycotope assets we acquired. The transaction also underscores the ongoing interest from major industry players in the expertise Pentixapharm maintains and develops.”
The July 2024 acquisition of Glycotope’s target discovery business included a portfolio of preclinical oncology antibodies, a unique tumor target database, a discovery platform, and associated intellectual property. Also transferred to Pentixapharm were various patents, licenses, and licensing agreements.
About Pentixapharm
Pentixapharm is a clinical-stage biotech company focused on discovering and developing novel targeted radiopharmaceuticals. With offices in Berlin and Würzburg, Germany, the company is dedicated to developing first-in-class, ligand-based radiopharmaceuticals with clear commercial pathways for diagnostic and therapeutic applications. Its pipeline includes CXCR4-targeted compounds and early-stage radionuclide-antibody conjugates targeting hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.
For more information, please contact:
Pentixapharm Holding AG
Phillip Eckert, Investor Relations
Tel. +49 30 94893232
“`
